Goldman Sachs reiterated its Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares with a steady price target of $78.00. The firm's analyst highlighted Ultragenyx's fourth-quarter total ...
9don MSN
Jay and Pamela both have Osteogenesis Imperfecta Type 3, a condition that causes fragile bones. Both get around in motorized ...
Reports Q4 revenue $164.88M, consensus $158.71M. “We have created a next-generation rare disease company on a pathway to profitability with ...
Jay and Pamela take on their health struggles while also gearing up for their wedding in new docuseries "Jay and Pamela," ...
Charlotte Proud, a Sunderland University apprentice born with Osteogenesis Imperfecta (Brittle Bone Disease), is determined ...
Parade on MSN10d
'Jay & Pamela': Meet TLC's Newest Couple With the Same Super Rare Genetic Disorder (Exclusive Trailer)A new TLC reality series, Jay & Pamela, is just around the corner—and its stars are an engaged couple born with the same ...
Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report January-December 2024. The full report is available on the Company's website. “Stronger liquidity will ensure our ...
TLC seems particularly busy lately, announcing some new shows that take the channel in familiar directions and at least one ...
Mereo BioPharma shifts focus to rare diseases with setrusumab showing strong results for Osteogenesis Imperfecta. Learn more on MREO stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback